FDA: Patients Who Respond Well to CML Drug Don’t Have to Stay on It Forever

The FDA updated the label of a cancer drug to include that certain patients with early chronic myeloid leukemia (CML) may be able to stop taking the treatment after they’ve responded well to it over time. The new update indicates that patients with CML who have been taking Tasigna (nilotinib) for 3 years or more, and whose leukemia has responded to treatment based on FDA criteria, may be able to discontinue use of the cancer drug. In the past, patients with CML remained on the drug indefinitely. While musculoskeletal symptoms such as body aches, bone pain and pain in extremities are among the most common side effects, Tasigna’s labeling contains a black-box warning alerting doctors and patients about the risk of abnormal heart rhythm (QT prolongation) and sudden death. Posted December 22, 2017. Via FDA.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Recommend More Articles Like This?

Show Comments (0)
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x